Oragenics announces early toxicology data for intranasal COVID-19 vaccine

Aug. 24, 2022 7:18 AM ETOragenics, Inc. (OGEN)GSKBy: Dulan Lokuwithana, SA News Editor1 Comment

Mutating Virus Variant


  • Development-stage biotech Oragenics, Inc. (NYSE:OGEN) announced initial data on Wednesday from an ongoing Good Laboratory Practice (GLP) toxicology study for NT-CoV2-1, an intranasal COVID-19 vaccine candidate.
  • The data, generated from a rabbit model, indicate a safety profile and immune responses for NT-CoV2-1, the company said, adding that the readout is expected to support regulatory filings required to advance the candidate in a Phase 1 trial.
  • The final toxicology report, which will include data from ongoing histopathology evaluation, is expected by the year-end. The company plans to start the Phase 1 trial for NT-CoV2-1 by early 2023.
  • “We believe our intranasal vaccine candidate will have the potential to reduce transmission and offers a needle-free COVID-19 vaccine option,” OGEN's Chief Executive Kimberly Murphy said.
  • A former executive at GSK (GSK), Murphy took the leadership of OGEN in June.

This was corrected on 09/05/2022 at 10:34 AM. This article was corrected to reflect the accurate ticker symbol for Oragenics.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.